FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

• Lucie C. Kompier,

  Affiliation Department of Pathology, Erasmus MC, Rotterdam, The Netherlands

  ⨯
• Irene Lurkin,

  Affiliation Department of Pathology, Erasmus MC, Rotterdam, The Netherlands

  ⨯
• Madelon N. M. van der Aa,

  Affiliation Department of Pathology, Erasmus MC, Rotterdam, The Netherlands

  ⨯
• Bas W. G. van Rhijn,

  Affiliation Department of Urology, University Health Network, Toronto General Hospital, Toronto, Canada

  ⨯
• Theo H. van der Kwast,

  Affiliation Department of Laboratory Medicine and Pathobiology, University Health Network, Toronto General Hospital, Toronto, Canada

  ⨯
• Ellen C. Zwarthoff

  * E-mail: e.zwarthoff@erasmusmc.nl

  Affiliation Department of Pathology, Erasmus MC, Rotterdam, The Netherlands

  ⨯